SCHEMBL15529482

SCHEMBL15529482

O=C(Nc1ccc(C2CCN(C(=O)c3ccccc3)C2)cc1)N1CC(c2cccnc2)C1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 9/20 0.60
NPC1 O15118 6/20 0.60
RAB9A P51151 6/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
TP53 P04637 5/20 0.60
MAPT P10636 4/20 0.57
LMNA P02545 2/20 0.57
NFKB1 P19838 2/20 0.57
NFKB2 Q00653 2/20 0.57
RELA Q04206 2/20 0.57
TSHR P16473 1/20 0.54
GRIN2B Q13224 1/20 0.54
STAT1 P42224 1/20 0.54
CYP3A4 P08684 2/20 0.52
ATM Q13315 1/20 0.52
HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15528883 0.96 NAMPT (0.66) NAMPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL15529003 0.93 NAMPT (0.61) NAMPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL15530184 0.90 NPC1 (0.61) NAMPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL16228558 0.88 NAMPT (0.51) NAMPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL15528995 0.88 NAMPT (0.50) NAMPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL15529632 0.87 NAMPT (0.71) NAMPTHTT
SCHEMBL15529273 0.87 NAMPT (0.71) NAMPTHTT
SCHEMBL15529370 0.87 NPC1 (0.57) NAMPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL15529115 0.87 NPC1 (0.57) NAMPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL15529032 0.86 NPC1 (0.56) NAMPTNPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US claimed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP claimed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US claimed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO claimed
US-9758511-B2 NAMPT inhibitors ABBVIE INC. (US) 2017-09-12 US disclosed
US-20160168134-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-16 US disclosed
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP disclosed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US disclosed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168134-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT NAMPT 1/4885NPC1 88/4885RAB9A 2177/4885
US-20140336168-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT NAMPT 1/4885NPC1 88/4885RAB9A 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.